220 related articles for article (PubMed ID: 24978921)
1. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.
Hoang LL; Tacha DE; Qi W; Yu C; Bremer RE; Chu J; Haas TS; Cheng L
Arch Pathol Lab Med; 2014 Jul; 138(7):943-9. PubMed ID: 24978921
[TBL] [Abstract][Full Text] [Related]
2. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
[TBL] [Abstract][Full Text] [Related]
3. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?
Riedel I; Liang FX; Deng FM; Tu L; Kreibich G; Wu XR; Sun TT; Hergt M; Moll R
Eur J Cell Biol; 2005 Mar; 84(2-3):393-405. PubMed ID: 15819416
[TBL] [Abstract][Full Text] [Related]
4. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
5. Uroplakin II outperforms uroplakin III in diagnostically challenging settings.
Smith SC; Mohanty SK; Kunju LP; Chang E; Chung F; Carvalho JC; Paner GP; Hansel DE; Luthringer DJ; de Peralta-Ventrurina MN; Amin MB
Histopathology; 2014 Jul; 65(1):132-8. PubMed ID: 24382161
[TBL] [Abstract][Full Text] [Related]
6. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
7. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder.
Sledge DG; Patrick DJ; Fitzgerald SD; Xie Y; Kiupel M
Vet Pathol; 2015 Jan; 52(1):74-82. PubMed ID: 24608632
[TBL] [Abstract][Full Text] [Related]
8. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL; Røge R; Nielsen S
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):326-332. PubMed ID: 35510771
[TBL] [Abstract][Full Text] [Related]
10. Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder.
Klopfer K; Delahunt B; Adamson M; Samaratunga H
Anticancer Res; 2014 Nov; 34(11):6779-84. PubMed ID: 25368291
[TBL] [Abstract][Full Text] [Related]
11. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
[TBL] [Abstract][Full Text] [Related]
12. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
13. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.
Ogawa K; St John M; Luiza de Oliveira M; Arnold L; Shirai T; Sun TT; Cohen SM
Toxicol Pathol; 1999; 27(6):645-51. PubMed ID: 10588545
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
15. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
[TBL] [Abstract][Full Text] [Related]
17. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas.
Kaufmann O; Volmerig J; Dietel M
Am J Clin Pathol; 2000 May; 113(5):683-7. PubMed ID: 10800401
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
[TBL] [Abstract][Full Text] [Related]
19. Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
Tadin T; Krpina K; Štifter S; Babarović E; Jonjić N
Pathol Res Pract; 2014 May; 210(5):279-84. PubMed ID: 24553301
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
